Merck's Remigromig Shows Efficacy for Diabetic Macular Edema in Trial
Merck (MRK) announced positive results from its Phase 2b/3 trial of remigromig, an intravitreal injection therapy for diabetic macular edema. The drug demonstrated efficacy comparable to ranibizumab, a treatment marketed by Roche for the same condition. Diabetic macular edema is a leading cause of vision loss among diabetes patients and represents a significant unmet medical need in ophthalmology. Merck's success with remigromig could position it as a competitive alternative to existing therapies like ranibizumab, potentially expanding its footprint in the treatment landscape. The results are seen as an important step for Merck’s pipeline development and may attract investor interest due to the high demand for effective DME treatments.
Tickers: $MRK $RHHBY $ROG $ROP
Topics: Diabetic Macular Edema (DME) Drug Development Pharmaceuticals